ArticleArthritis & rheumatology (Hoboken, N.J.)2020
Antiphospholipid Antibodies in Critically Ill Patients With COVID-19.
Article in Arthritis & rheumatology (Hoboken, N.J.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 6 syntheses or guidelines pooled it, 179 citations in OpenAlex.
- Antiphospholipid Antibodies and COVID-19: A Systematic Review of Clinical Implications.Immunity, inflammation and disease · 2025Pooled it
- Antiphospholipid antibody-related hepatic vasculitis in a juvenile after non-severe COVID-19: a case report and literature review.Frontiers in immunology · 2024Pooled it
- Systematic Review of Antiphospholipid Antibodies in COVID-19 Patients: Culprits or Bystanders?Current rheumatology reports · 2021Pooled it
- A Review of Pathophysiology, Clinical Features, and Management Options of COVID-19 Associated Coagulopathy.Shock (Augusta, Ga.) · 2021Pooled it
- Pooled it
- Autoimmune and Rheumatic Manifestations Associated With COVID-19 in Adults: An Updated Systematic Review.Frontiers in immunologyPooled it
- Immunological Mechanisms and Machine Learning Applications in Post-COVID-19 Syndrome: A Narrative Review.Microorganisms · 2026Article
- Article
- Autoantibodies targeting angiotensin-converting enzyme 2 are prevalent and not induced by SARS-CoV-2 infection.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- The New Occurrence of Antiphospholipid Syndrome in Severe COVID-19 Cases with Pneumonia and Vascular Thrombosis Could Explain the Post-COVID Syndrome.Biomedicines · 2025Article
- Autoantibodies in long COVID in a black/mixed population compared with recovered and pre-pandemic controls.Frontiers in immunology · 2025Article
- Characteristics of Oral Adverse Effects following COVID-19 Vaccination and Similarities with Oral Symptoms in COVID-19 Patients: Taste and Saliva Secretory Disorders.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2025Review
- Pathological Sequelae of SARS-CoV-2: A Review for Clinicians.The Yale journal of biology and medicine · 2024Review
- Comparison of anti-phospholipid antibody titers before and after SARS-CoV-2 mRNA vaccination in hospital staff.Vaccine: X · 2024Article
- Clinical features and treatment of 70 children with lupus anticoagulant-hypoprothrombinemia syndrome: a retrospective study from a single center in China.Research and practice in thrombosis and haemostasis · 2024Article
- IgA Anti-β2-Glycoprotein I Antibodies as Markers of Thrombosis and Severity in COVID-19 Patients.Viruses · 2024Article
- The development of anticyclic citrullinated peptide (anti-CCP) antibody following severe COVID-19.Immunity, inflammation and disease · 2024Article
- Autoantibodies in COVID-19: implications for disease severity and clinical outcomes.Frontiers in immunology · 2024Review
- The spectrum of COVID-19-associated chorioretinal vasculopathy.American journal of ophthalmology case reports · 2023Article
- Molecular mimicry and autoimmunity in the time of COVID-19.Journal of autoimmunity · 2023Review
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors at 1 institution in 1 country.
Funding
Abstract
objectiveCoagulopathy is one of the characteristics observed in critically ill patients with coronavirus disease 2019 (COVID-19). Antiphospholipid antibodies (aPLs) contribute to coagulopathy, though their role in COVID-19 remains unclear. This study was undertaken to determine the prevalence and characteristics of aPLs in patients with COVID-19.
methodsSera collected from 66 COVID-19 patients who were critically ill and 13 COVID-19 patients who were not critically ill were tested by chemiluminescence immunoassay for anticardiolipin antibodies (aCLs), anti-β
resultsOf the 66 COVID-19 patients in critical condition, aPLs were detected in 31 (47% ). Antiphospholipid antibodies were not present among COVID-19 patients who were not in critical condition. The IgA anti-β
conclusionAntiphospholipid antibodies were common in critically ill patients with COVID-19. Repeated testing demonstrating medium to high titers of aPLs and the number of aPL types a patient is positive for may help in identifying patients who are at risk of developing cerebral infarction. Antiphospholipid antibodies may be transient and disappear within a few weeks, but in genetically predisposed patients, COVID-19 may trigger the development of an autoimmune condition similar to the antiphospholipid syndrome (APS), referred to as "COVID-19-induced APS-like syndrome." Long-term follow-up of COVID-19 patients who are positive for aPLs would be of great importance in understanding the pathogenesis of this novel coronavirus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.